What Is ADSTILADRIN?

ADSTILADRIN (nadofaragene firadenovec-vncg) is the FIRST and ONLY FDA-approved gene therapy delivered directly in the bladder for high-risk non–muscle-invasive bladder cancer (NMIBC).

You can start this treatment after Bacillus
Calmette-Guérin (BCG) stops working.

ADSTILADRIN IS…

Targeted treatment icon

A localized gene therapy

It causes the immune system to fight NMIBC directly in the bladder.

Calendar icon

Given ONCE EVERY 3 MONTHS

This keeps the number of treatment appointments low.

Bladder icon

Delivered directly to the bladder

It is given via catheterand stays in the bladder. It doesn’t spread throughout the body. This may reduce side effects.

Monotherapy icon

A monotherapy

This means using just one type of medicine to treat a health problem. You do not need to combine ADSTILADRIN with any other medicine for it to work.

ADSTILADRIN IS NOT…

Helping bladder icon

Chemotherapy or BCG treatment

It is an intravesical treatment option that may help you keep your bladder if BCG isn’t working as it should.

Person with bladder icon

Impacting your entire
body

It causes your immune system to attack the cancer in the bladder. It doesn’t attack your entire body. This may reduce side effects.

Gene therapy icon

Changing your genes

Instead, it works with your immune system to stop cancer cell growth and kill cancer cells in the bladder.

Healthcare professional icon

A treatment that may require you to
change doctors

Your doctor may conveniently remain the same since ADSTILADRIN may be given by your urologist in their office.

How ADSTILADRIN works

ADSTILADRIN is a one-of-a-kind gene therapy that fights high-risk NMIBC directly in the bladder.

  • ADSTILADRIN uses a viral vector to carry a gene called
    interferon alpha 2B (IFNα2b) into the cells of the bladder lining
  • Once inside the bladder cells, the vector breaks down, and the IFNα2b gene makes its way into the cell nucleus, where it helps the body produce and secrete a similarly named protein called IFNα2b
  • The IFNα2b protein works with your immune system directly and indirectly to stop cancer cell growth and kill cancer cells in the bladder
Click to play video

Important Safety Information

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

  • High-risk non–muscle-invasive bladder cancer (NMIBC)
  • Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
  • Carcinoma in situ (CIS) with or without other high-grade tumors

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN?
Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN?
Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN.

What should I tell my healthcare provider?
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN?
The most common side effects of ADSTILADRIN include:
Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

What other information should I know about using ADSTILADRIN?
For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-74641-888-337-7464.

Please see full Prescribing Information.

You are now leaving the ADSTILADRIN website.